Target
TBK1/IKKε
Halting the Inflammation Process
- KO mouse protected from hepatic steatosis on HFD
- Inhibitor lowers liver cholesterol and triglycerides in mouse in vivo model
- Inhibitor decreases liver enzymes in several NASH models
- IST POC trial with known inhibitor confirms liver fat loss
- Documented human safety for this target
- Implicated as I/O approach to cancer
- Active site SBDD enabled
![tbk1-img-left](https://elgiatherapeutics.com/wp-content/uploads/2020/12/tbk1-img-left.gif)
![tbk1-img-right](https://elgiatherapeutics.com/wp-content/uploads/2020/12/tbk1-img-right.gif)
Lorem Ipsum Dolore Sectum
![tbk1-alt](https://elgiatherapeutics.com/wp-content/uploads/2020/12/tbk1-alt.gif)
![tbk1-ast](https://elgiatherapeutics.com/wp-content/uploads/2020/12/tbk1-ast.gif)
![tbk1-alp](https://elgiatherapeutics.com/wp-content/uploads/2020/12/tbk1-alp.gif)